6月24日，据CDE官网消息，韦恩生物科技有限公司联合申请药品“WBD156胶囊”，获得临床试验默示许可，受理号CXHL2500395。
公示信息显示，药品“WBD156胶囊”适应症：超重或肥胖症。
韦恩生物科技有限公司，成立于2020年，位于上海市，是一家以从事科技推广和应用服务业为主的企业。企业注册资本5000万人民币，实缴资本3000万人民币。
通过天眼查大数据分析，韦恩生物科技有限公司知识产权方面有商标信息3条，专利信息4条，此外企业还拥有行政许可4个。
主要股东信息显示，韦恩生物科技有限公司由上海伊诺维迅企业管理合伙企业（有限合伙）持股40%、上海汉国实业集团有限公司持股35%、上海礼德希普企业管理合伙企业（有限合伙）持股25%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.